Genon Laboratories Ltd, commonly referred to as Genon Labs, is a leading player in the pharmaceutical and biotechnology industry, headquartered in Great Britain. Founded in 2005, the company has established a strong presence in key operational regions across Europe and North America, focusing on innovative solutions in drug development and manufacturing. Specialising in high-quality active pharmaceutical ingredients (APIs) and advanced drug delivery systems, Genon Labs is recognised for its commitment to research and development, ensuring that its products meet the highest industry standards. The company has achieved significant milestones, including several successful partnerships with major pharmaceutical firms, solidifying its market position as a trusted provider of cutting-edge solutions. With a dedication to excellence and innovation, Genon Laboratories Ltd continues to make strides in enhancing healthcare outcomes globally.
How does Genon Laboratories Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Genon Laboratories Ltd's score of 66 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Genon Laboratories Ltd, headquartered in Great Britain, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of SYNLAB AG, which influences its climate commitments and emissions reporting. As part of its corporate family relationship, Genon Laboratories Ltd inherits emissions data and reduction initiatives from SYNLAB AG. However, there are no documented reduction targets or specific climate pledges outlined for Genon Laboratories Ltd at this time. The absence of direct emissions data and reduction targets suggests that the company may still be in the process of establishing its own climate strategy or aligning with the broader initiatives of its parent organization. As the industry increasingly focuses on sustainability, it is essential for Genon Laboratories Ltd to develop and communicate its climate commitments to meet stakeholder expectations and regulatory requirements.
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 22,155,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 16,535,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 000,000,000 | 000,000,000 |
Genon Laboratories Ltd's Scope 3 emissions, which decreased by 1% last year and decreased by approximately 1% since 2023, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 87% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Genon Laboratories Ltd has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.